Table 1.
Demographics | Total Cohort n=303 (100%) | Year < 2004 n=159 (52%) | Year ≥ 2004 n=144 (48%) | P |
---|---|---|---|---|
Age, years | 72.2 ± 13.3 | 71.6 ± 12.7 | 72.9 ± 13.9 | .40 |
Sex, female | 168 (55%) | 89 (56%) | 79 (55%) | .85 |
Caucasian race | 257 (86%) | 136 (87%) | 121 (85%) | .60 |
Transfer, yes | 101 (33%) | 46 (29%) | 55 (38%) | .09 |
Comorbidities | ||||
Hypertension | 225 (74%) | 110 (69%) | 115 (80%) | .03 |
CKD | 84 (28%) | 36 (23%) | 48 (33%) | .04 |
CHF | 132 (44%) | 62 (39%) | 70 (49%) | .09 |
PVD | 142 (47%) | 72 (45%) | 70 (49%) | .56 |
COPD | 109 (36%) | 43 (27%) | 66 (46%) | .001 |
Diabetes | 77 (25%) | 33 (21%) | 44 (31%) | .05 |
CAD | 170 (56%) | 82 (52%) | 88 (61%) | .10 |
Atrial fibrillation | 152 (50%) | 76 (48%) | 76 (53%) | .39 |
Hyperlipidemia | 119 (39%) | 35 (22%) | 84 (58%) | <.001 |
Any smoking history | 154 (51%) | 69 (43%) | 85 (59%) | .01 |
Current smoker | 53 (17%) | 18 (11%) | 35 (24%) | .003 |
Medications | ||||
Beta blocker | 153 (51%) | 57 (36%) | 96 (67%) | <.001 |
Anticoagulation | 70 (23%) | 32 (20%) | 38 (26%) | .20 |
Statin | 98 (32%) | 25 (16%) | 73 (51%) | <.001 |
Antiplatelet therapy, any | 136 (45%) | 56 (35%) | 80 (56%) | <.001 |
Aspirin | 127 (42%) | 51 (32%) | 76 (53%) | <.001 |